摘要
AIM: To evaluate the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) combined with huachansu (cinobufagin) injection treatment in patients with locally advanced or metastatic gallbladder carcinoma (GBC), and to assess the quality of life (QOL) of such patients. METHODS: Twenty-fi ve patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine (1000 mg/m2) over 30 min on days 1 and 8, 2 h infusion of oxaliplatin (120 mg/m2) on day 1, and 2-3 h infusion of huachansu (20 mL/m2) on days -3-11, every 3-4 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. QOL of patients was assessed by the EORTC QLQ-C30 at baseline, at the end of the fi rst, third and sixth chemotherapy cycles, and 1 mo after the treatment. RESULTS: Among the 25 patients with a median age of 64 years (range 42-78 years), 23 were evaluable in the study. A total of 137 cycles of therapy were performed and the median cycle was 5 (range 1-8) per patient. Out of the 23 patients whose response couldbe evaluated, 8 partial responses (PR) were observed (34.8%), while 7 patients (30.4%) demonstrated a stable disease (SD). The disease control rate was 65.2%. Progression of cancer was observed in 8 (34.8%) patients. The median progression-free and overall survival time was 5.8 mo (95% CI: 4.5-7.1 mo) and 10.5 mo, respectively. The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively. Non-hematologic toxicity ranged from mild to moderate. No death occurred due to toxicity. The QOL of patients was improved after chemotherapy, and the scores of QOL were increased by 10 to 20 points. CONCLUSION: GEMOX combined with huachansu (cinobufagin) injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.
AIM： To evaluate the efficacy and safety of gemcitabine-oxaliplatin （GEMOX） combined with huachansu （cinobufagin） injection treatment in patients with locally advanced or metastatic gallbladder carcinoma （GBC）, and to assess the quality of life （QOL） of such patients. METHODS： Twenty-fi ve patients with locally advanced or metastatic GBC were treated with intravenous gemcitabine （1000 mg/m^2） over 30 min on days 1 and 8, 2 h infusion of oxaliplatin （120 mg/m^2） on day 1, and 2-3 h infusion of huachansu （20 mL/m^2） on days -3-11, every 3-4 wk. Treatment was continued until occurrence of unacceptable toxicity or disease progression. QOL of patients was assessed by the EORTC QLQ-C30 at baseline, at the end of the fi rst, third and sixth chemotherapy cycles, and 1 mo after the treatment. RESULTS： Among the 25 patients with a median age of 64 years （range 42-78 years）, 23 were evaluable in the study. A total of 137 cycles of therapy were performed and the median cycle was 5 （range 1-8） per patient. Out of the 23 patients whose response couldbe evaluated, 8 partial responses （PR） were observed （34.8%）, while 7 patients （30.4%） demonstrated a stable disease （SD）. The disease control rate was 65.2%. Progression of cancer was observed in 8 （34.8%） patients. The median progression-free and overall survival time was 5.8 mo （95% CI： 4.5-7.1 mo） and 10.5 mo, respectively. The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Anemia grade 2 was seen in 16.0%, neutropenia grade 3 in 8.0% and thrombocytopenia grade 3 in 24.0% of patients, respectively. Non-hematologic toxicity ranged from mild to moderate. No death occurred due to toxicity. The QOL of patients was improved after chemotherapy, and the scores of QOL were increased by 10 to 20 points. CONCLUSION： GEMOX combined with huachansu （cinobufagin） injection is well tolerated, effective, thus improving the QOL of patients with advanced GBC.
关键词
胆囊癌
药物治疗
联合疗效
生活品质
Gallbladder carcinoma
Gemcitabine
Oxaliplatin
Huachansu injection
Quality of life
